Skip to content

Dapagliflozin and acute heart failure

A Study to Test Dapagliflozin in Patients with Acute Heart Failure

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150617022794N3
Enrollment
200
Registered
2024-06-09
Start date
2024-07-05
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure. Systolic (congestive) heart failure

Interventions

Intervention 1: Intervention group: 40 mg intravenous furosemide determined by amount of congestion. In addition, patients will receive 10 mg oral Dapagliflozin daily for 5 days (Kimia Pharmaceutical

Sponsors

Semnan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Acute heart failure BNP>100 pg/ml receiving IV furosemide Evidence of congestion

Exclusion criteria

Exclusion criteria: Serum glucose < 80 mg/dL Type 1 diabetes mellitus Systolic blood pressure < 90 mmHg Requirement of inotropic therapy hypersensitivity to SGLT-2 inhibitors Already receiving an SGLT2 inhibitor Pregnancy History of DKA Acute MI

Design outcomes

Primary

MeasureTime frame
Ejection fraction. Timepoint: At admission and 5 days after receiving the medications and at study termination. Method of measurement: echocardiography.

Secondary

MeasureTime frame
Serum level of Sirtuin-1. Timepoint: At admission and 5 days after receiving the medications. Method of measurement: ELISA.;Worsening of clinical conditions. Timepoint: At release till 8 weeks. Method of measurement: Readmission and phone call.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHooman Bakhshande

ShaRajaie Cardiovascular, Medical & Research Center

hooman.bakhsande@gmail.com22042026 -021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026